Alto Neuroscience, Inc. (NYSE:ANRO – Get Free Report) has been given an average recommendation of “Moderate Buy” by the seven analysts that are currently covering the firm, Marketbeat reports. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $24.40.
A number of research firms have recently commented on ANRO. William Blair reiterated an “outperform” rating on shares of Alto Neuroscience in a research report on Tuesday, September 10th. Rodman & Renshaw lowered Alto Neuroscience from a “buy” rating to a “neutral” rating in a research report on Wednesday. Wedbush cut Alto Neuroscience from an “outperform” rating to a “neutral” rating and reduced their price objective for the company from $29.00 to $4.00 in a research note on Wednesday. Finally, Robert W. Baird lowered their target price on shares of Alto Neuroscience from $32.00 to $10.00 and set an “outperform” rating on the stock in a research report on Wednesday.
Check Out Our Latest Stock Report on Alto Neuroscience
Institutional Inflows and Outflows
Alto Neuroscience Trading Down 70.0 %
ANRO stock opened at $4.36 on Thursday. The company has a debt-to-equity ratio of 0.04, a current ratio of 19.85 and a quick ratio of 19.85. Alto Neuroscience has a twelve month low of $4.26 and a twelve month high of $24.00. The company’s 50 day moving average is $12.22 and its two-hundred day moving average is $12.48.
Alto Neuroscience (NYSE:ANRO – Get Free Report) last posted its earnings results on Tuesday, August 13th. The company reported ($0.60) EPS for the quarter, beating analysts’ consensus estimates of ($0.67) by $0.07. As a group, equities research analysts expect that Alto Neuroscience will post -2.63 EPS for the current fiscal year.
About Alto Neuroscience
Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.
Further Reading
- Five stocks we like better than Alto Neuroscience
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- Chinese Stocks Cool Off: Time to Buy the Dip in These 2 Stocks?
- Transportation Stocks Investing
- Goldman Sachs Highlights 3 Top Short Squeeze Stocks to Watch
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- Walmart is Up 56% YTD, Is it Still a Top Consumer Staples Stock?
Receive News & Ratings for Alto Neuroscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alto Neuroscience and related companies with MarketBeat.com's FREE daily email newsletter.